Alkermes reports positive top-line Phase Ib trial data for ALKS 7290
ALKS 7290 was generally well tolerated at all doses in the study, which enrolled 88 healthy volunteers and 50 adults.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance